Leveraging over a decade of electrophysiology expertise, the NaV1.9 assay, alongside Metrion’s unique combination of ion channel expertise, bespoke assays and pain research services, enables researchers to overcome traditional limitations of NaV1.9 screening and generate reproducible and decision-ready data.

The inaugural feature, published 19th January, highlights the UK’s fastest-growing private companies developing or selling unique, proprietary technologies, and is backed by Singer Capital Markets, HSBC Innovation Banking and BDO.

Organised by Metrion, AstraZeneca and the British Pharmacological Society, the Cambridge lon Channel Forum is an environment for industry and academic scientists working within the ion channel field to share data and ideas.